Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22661899 | 1.00 | KMT2A (0.48) | KMT2ABRD4CYP2C19ELANEEHMT2 | |
| SCHEMBL1508566 | 1.00 | KMT2A (0.48) | KMT2ABRD4CYP2C19ELANEEHMT2 | |
| SCHEMBL2491074 | 0.86 | KMT2A (0.48) | KMT2ACYP2C19EHMT2MEN1MAPT | |
| SCHEMBL1508950 | 0.83 | KMT2A (0.50) | KMT2ACYP2C19ELANEEHMT2MEN1 | |
| SCHEMBL1508846 | 0.83 | KMT2A (0.50) | KMT2ACYP2C19ELANEEHMT2MEN1 | |
| SCHEMBL22661866 | 0.83 | KMT2A (0.50) | KMT2ACYP2C19ELANEEHMT2MEN1 | |
| SCHEMBL2489351 | 0.83 | KMT2A (0.42) | KMT2AELANEEHMT2MEN1MAPT | |
| SCHEMBL2492931 | 0.83 | KMT2A (0.42) | KMT2AELANEEHMT2MEN1MAPT | |
| SCHEMBL2487236 | 0.79 | KMT2A (0.39) | KMT2ABRD4MEN1MAPTHSD11B1 | |
| SCHEMBL23341192 | 0.75 | OPRM1 (0.35) | KMT2ABRD4MEN1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370800-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2022-06-28 | — | — | US | disclosed |
| EP-3580205-B1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLDIKETOPIPERAZINES AND OF A KEY INTERMEDIATE OF DS-5272 | FIS FABBRICA ITALIANA SINTETICI SPA (IT) | 2021-05-05 | — | — | EP | disclosed |
| US-20200377521-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLDIKETOPIPERAZINES AND OF A KEY INTERMEDIATE OF DS-5272 | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2020-12-03 | — | — | US | disclosed |
| US-10836778-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | F.I.S.—Fabbrica Italiana Sintetici S.p.A. (IT) | 2020-11-17 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| US-8404691-B2 | Imidazothiazole derivatives having proline ring structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2298778-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIROÝ2.5¨OCTANE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010082612-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | 第一三共株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172362-A1 | Imidazothiazole Derivatives Having Proline Ring Structure | MDM2, TP53, TP53BP1 | KMT2A 1912/4885BRD4 1113/4885CYP2C19 4314/4885 |
| US-10836778-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | DHPS, DUS2, RPS2 | KMT2A 969/4885BRD4 968/4885CYP2C19 1558/4885 |
| US-11370800-B2 | Process for the preparation of cyclopropyldiketopiperazines and of a key intermediate of DS-5272 | DHPS, DUS2, RPS2 | KMT2A 969/4885BRD4 968/4885CYP2C19 1558/4885 |
| US-20200377521-A1 | PROCESS FOR THE PREPARATION OF CYCLOPROPYLDIKETOPIPERAZINES AND OF A KEY INTERMEDIATE OF DS-5272 | DHPS, DUS2, RPS2 | KMT2A 969/4885BRD4 968/4885CYP2C19 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.